» Articles » PMID: 17548493

Modulation of the Cellular Accumulation and Intracellular Activity of Daptomycin Towards Phagocytized Staphylococcus Aureus by the P-glycoprotein (MDR1) Efflux Transporter in Human THP-1 Macrophages and Madin-darby Canine Kidney Cells

Overview
Specialty Pharmacology
Date 2007 Jun 6
PMID 17548493
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

P-glycoprotein (P-gp; MDR1), a major efflux transporter, recognizes various antibiotics and is present in macrophages. We have examined its effect on the modulation of the intracellular accumulation and activity of daptomycin towards phagocytized Staphylococcus aureus (ATCC 25923) in human THP-1 macrophages, in comparison with MDCK epithelial cells (wild type and MDCK-MDR1 overexpressing P-gp; the bulk of the protein was immunodetected at the surface of all three cell types). Daptomycin displayed concentration-dependent intracellular activity (Hill equation pattern) in THP-1 and MDCK cells with (i) 50% effective drug extracellular concentration (EC(50); relative potency) and static concentrations at 9 to 10 times the MIC and (ii) maximal efficacy (E(max); CFU decrease at infinite extracellular drug concentration) at 1.6 to 2 log compared to that of the postphagocytosis inoculum. Verapamil (100 microM) and elacridar (GF 120918; 0.5 microM), two known inhibitors of P-gp, decreased daptomycin EC(50) (about threefold) in THP-1 and MDCK cells without affecting E(max). Daptomycin EC(50) was about three- to fourfold higher and accumulation in MDCK-MDR1 commensurately lower than in wild-type cells. In THP-1 macrophages, (i) verapamil and ATP depletion increased, and ouabain (an inducer of mdr1 [the gene encoding P-gp] expression) decreased the accumulation of daptomycin in parallel with that of DiOC(2) (a known substrate of P-gp); (ii) silencing mdr1 with duplex human mdr1 siRNAs reduced the cell content in immunoreactive P-gp to 15 to 30% of controls and caused an eight- to 13-fold increase in daptomycin accumulation. We conclude that daptomycin is subject to efflux from THP-1 macrophages and MDCK cells by P-gp, which reduces its intracellular activity against phagocytized S. aureus.

Citing Articles

Comparative in vitro efficacy of antibiotics against the intracellular reservoir of Staphylococcus aureus.

Beadell B, Yamauchi J, Wong-Beringer A J Antimicrob Chemother. 2024; 79(10):2471-2478.

PMID: 39073778 PMC: 11441993. DOI: 10.1093/jac/dkae241.


Daptomycin Physiology-Based Pharmacokinetic Modeling to Predict Drug Exposure and Pharmacodynamics in Skin and Bone Tissues.

Garreau R, Montange D, Grillon A, Jehl F, Ferry T, Bourguignon L Clin Pharmacokinet. 2022; 61(10):1443-1456.

PMID: 35972685 DOI: 10.1007/s40262-022-01168-5.


Intracellular Accumulation of Novel and Clinically Used TB Drugs Potentiates Intracellular Synergy.

Tanner L, Mashabela G, Omollo C, de Wet T, Parkinson C, Warner D Microbiol Spectr. 2021; 9(2):e0043421.

PMID: 34585951 PMC: 8557888. DOI: 10.1128/Spectrum.00434-21.


Are antibacterial effects of non-antibiotic drugs random or purposeful because of a common evolutionary origin of bacterial and mammalian targets?.

Dalhoff A Infection. 2020; 49(4):569-589.

PMID: 33325009 PMC: 7737717. DOI: 10.1007/s15010-020-01547-9.


Clinical Pharmacokinetics of Daptomycin.

Gregoire N, Chauzy A, Buyck J, Rammaert B, Couet W, Marchand S Clin Pharmacokinet. 2020; 60(3):271-281.

PMID: 33313994 DOI: 10.1007/s40262-020-00968-x.


References
1.
Sikri V, Pal D, Jain R, Kalyani D, Mitra A . Cotransport of macrolide and fluoroquinolones, a beneficial interaction reversing P-glycoprotein efflux. Am J Ther. 2004; 11(6):433-42. DOI: 10.1097/01.mjt.0000132643.69143.64. View

2.
Tran T, Mittal A, Aldinger T, Polli J, Ayrton A, Ellens H . The elementary mass action rate constants of P-gp transport for a confluent monolayer of MDCKII-hMDR1 cells. Biophys J. 2004; 88(1):715-38. PMC: 1305048. DOI: 10.1529/biophysj.104.045633. View

3.
Seral C, Barcia-Macay M, Mingeot-Leclercq M, Tulkens P, Van Bambeke F . Comparative activity of quinolones (ciprofloxacin, levofloxacin, moxifloxacin and garenoxacin) against extracellular and intracellular infection by Listeria monocytogenes and Staphylococcus aureus in J774 macrophages. J Antimicrob Chemother. 2005; 55(4):511-7. DOI: 10.1093/jac/dki059. View

4.
Leslie E, Deeley R, Cole S . Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol. 2005; 204(3):216-37. DOI: 10.1016/j.taap.2004.10.012. View

5.
Silverman J, Mortin L, Vanpraagh A, Li T, Alder J . Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis. 2005; 191(12):2149-52. DOI: 10.1086/430352. View